Phase 2 Colorectal Cancer Trial, Recruiting NCT07432399 Sponsor: Institute of Oncology Ljubljana Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT07432399
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with colon cancer confirmed through a tissue sample (biopsy or similar test)
  • People who are already scheduled to have surgery to remove their colon cancer
  • People whose treating doctor determines they are suitable to receive the study medications (lidocaine, dexamethasone, or a placebo) as part of the treatment plan around the time of surgery
  • People who are able to understand what the study involves and are willing to sign a consent form

Who may not be able to join:

  • People with a known allergy or sensitivity to lidocaine, dexamethasone, or any of the ingredients in these medications
  • People with severe liver problems
  • People with severe kidney problems
  • People with serious heart rhythm or electrical conduction problems
  • People who are pregnant or breastfeeding
  • People with serious uncontrolled health conditions that could affect their ability to take part in the study
  • People who are already taking part in another clinical trial that could affect this study's results
  • People whom the trial investigator considers unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 015879935

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institute of Oncology Ljubljana
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇸🇮 Slovenia

Primary endpoints

Change in Serum Cytokine Concentrations (IL-6, IL-8, IL-10, TNF-alpha)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov